Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor

Mutated lung adenocarcinoma

Chi-Cheng Li, MDa,b, Chih-Bin Lin, MDc,d, Sung-Chao Chu, MD, PhDa,d, Wei-Han Huang, MDe, Jen-Jyh Lee, MDc,d, Gee-Gwo Yang, MDc,d, Tso-Fu Wang, MDa,d, Yi-Feng Wu, MDa,d,*

Abstract
This observational study evaluated the treatment outcomes of clinical factors on the patients with lung adenocarcinoma with epidermal growth factor receptor mutations who received tyrosine kinase inhibitors as first-line treatment.

Patients with stage IIIb or IV lung adenocarcinoma with mutated epidermal growth factor receptor were enrolled retrospectively between March 2010 and December 2017. The hematologic markers on progression-free survival (PFS) and overall survival (OS) were analyzed.

Totally 190 patients were enrolled. In univariate analysis by hematologic markers, lower lymphocyte percentage and higher platelet count were associated with significantly poor PFS and OS. Multivariate analysis showed lower lymphocyte percentage was an independent poor prognostic factor for PFS and OS. Higher platelet count was an independent poor prognostic factor for OS only.

Patients with lung adenocarcinoma receiving tyrosine kinase inhibitors with lower lymphocyte percentage and higher platelet count had poorer prognoses compared with other patients.

Abbreviations: CIs = confidence intervals, EGFR = epidermal growth factor receptor, HRs = hazard ratios, NLR = neutrophil-to-lymphocyte ratio, OS = overall survival, PFS = progression-free survival, PLR = platelet-to-lymphocyte ratio, TKIs = tyrosine kinase inhibitors.

Keywords: lung adenocarcinoma, lymphocyte, platelet, prognosis, tyrosine kinase inhibitor

1. Introduction
According to the World Health Organization, lung adenocarcinoma is the major causes of mortality. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as the first-line therapy were used for treatment of EGFR-mutant lung adenocarcinoma for more than 10 years. And the response rates, progression-free survival (PFS) and overall survival (OS) had been improved by TKIs significantly. Although the response rate is high with EGFR TKIs as first-line treatment, there are still some patients with poor prognosis. Several biomarkers, including CA125 (cancer antigen 125), CEACAM (carcinoembryonic antigen-related cell adhesion molecule), neuron-specific enolase, and CYFRA21-1 (cytokeratin-19 fragments), all showed limited sensitivity and specificity.

Evidence by previous studies had been showed changes in a white blood count and platelet in cancer patients associated with the disease severity and survival. Lymphocytes also played critical roles in promoting systemic immune responses against tumors, and lymphocytopenia is associated with poor outcomes in many malignancies. High expression of CD8+ T lymphocytes, which predicts a favorable prognosis in lung adenocarcinoma was reported. Platelet played another important role in cancer prognosis, too. Thrombocytosis has been found which is associated with poorer cancer prognosis. Shorter OS rates observed for patients with many malignancies, included ovarian cancer, lung cancer, and breast cancer which was related to thrombocytosis at the time of diagnosis, and poor prognoses of patients with colorectal cancer before surgical therapy are related to high platelet counts. Sylman et al reported that platelet count is also a predictor of metastasis in patients with cancer. On the other hand, systemic inflammation also plays a role in cancer.
Inflammatory mediators are involved in cancer progression with apoptosis, angiogenesis, and DNA damage. The markers included the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Higher NLR or PLR has been reported to predict shorter PFS and OS in many solid cancers.

Awareness of newer prognostic factors might provide a potential direction for further improvement in treatment for EGFR-mutated non-small-cell lung cancer, especially adenocarcinoma, but no study has focused on hematologic and inflammatory markers in EGFR-mutant lung adenocarcinoma. In this study, we evaluated the effects of hematologic and inflammatory factors on the treatment outcomes of patients with advanced or metastatic lung adenocarcinoma with active EGFR mutations. All patients received TKIs as the first-line treatment.

2. Patients and methods

2.1. Patients and data collection

From March 1, 2010, to December 31, 2017, totally 840 patients were diagnosed newly with lung cancer in Buddhist Tzu Chi General Hospital, Hualien, Taiwan. There were 550 patients with adenocarcinoma, and 394 patients with stage IIIb or IV. Three hundred ninety patients with stage IIIb or IV lung adenocarcinoma had EGFR study (4 patients did not have EGFR study). In 390 patients, there were 193 patients showed EGFR-mutated, and 3 patients with EGFR-mutated received supportive care only. We enrolled the patients with stage IIIb or IV adenocarcinoma and received tyrosine kinase inhibitors as first line treatment only in this retrospective study. (Fig. 1)

According to the World Health Organization pathology classification, lung adenocarcinoma was confirmed by biopsy. All patients received serial imaging studies at the initial diagnosis for staging, including computed tomography, whole-body bone scan, positron emission tomography scan, and brain imaging. Tumor staging was recorded by the seventh American Joint Committee on Cancer staging system. All the patients had an EGFR mutation examination of the tumor specimen, and the results showed active EGFR mutations in exons 18, 19, 20, or 21 in all patients. And then they received EGFR TKIs as first-line therapy, including afatinib, erlotinib, or gefitinib. The choice of EGFR TKI was by the decision of their attending physicians. Baseline clinical characteristics were determined through a retrospective chart review, including age at diagnosis, sex, smoking status, mutation type, and TKIs used. Malignant pleural effusion was diagnosed by either pleural effusion cytology or a pleural biopsy. Complete blood counts, including total leukocyte counts with a different count, hemoglobin, and platelet count, were also recorded. NLR and PLR were also calculated from the data of complete blood counts.

Mutational analysis of EGFR gene was done as described in a previous study. Briefly, formalin-fixed, paraffin-embedded tissues were used. An EGFR RGQ Kit (Qiagen, Hilden, Germany) was used for the analysis of mutations in EGFR, which utilizes amplification refractory mutation-specific polymerase chain reaction and Scorpion technologies for detection and direct sequencing.

PFS was recorded as the duration between the start of TKI treatment and the date of progression. And OS was defined as the duration from the start of TKI treatment to the time of all-cause death. All enrolled patients were followed up until death or the end of December 2018. This retrospective study was approved by the Institutional Review Board of Buddhist Tzu Chi General Hospital (IRB108-48-B). Informed written consent was waived because the study was a retrospective data analysis.

Figure 1. Study flowchart.
2.2. Statistical analyses

MedCalc (Mariakerke, Belgium) was used for analysis with median and hazard ratios (HRs) and 95% confidence intervals (CIs). Kaplan–Meier curves and the log-rank test were used for analysis of PFS and OS. Univariate and multivariate analyses were executed using Cox proportional-hazards regression, and all variables were included for multivariate analysis to assess the effect of each variable after univariate analyses. Stepwise variable selection was used to develop a reduced multivariate model, including variables with \( P < .1 \) and removing variables with \( P > .2 \). Because of above, many factors, for example age, gender, stage (IIIb vs IV), WBC count, Hb, did not show the \( P \)-value in multivariate analysis due to no significant difference in univariate test. Two-sided with the level of statistical significance set at \( P < .05 \) was used in all results.

3. Results

3.1. Clinical features of patients

Overall, 190 patients, including 87 male (45.8%) and 103 female (54.2%), were enrolled. The median follow-up duration was 17.9 months (range, 0.5–91.3 months). The clinical features of this study population, such as age, sex, smoking history, stage, EGFR mutation, drugs used, malignant pleural effusion, and brain metastasis, are summarized in Table 1. The median age was 70 years (range, 42–95). In all patients, adenocarcinoma was confirmed by pathologists. Twenty-one (11.1%) and 169 (88.9%) patients were at TNM stages IIIb and IV, respectively. As the type of EGFR mutation, 89 patients (46.8%) were confirmed with mutation of L858R, 89 (46.8%) with exon 19 deletions, and the remaining 12 (6.3%) had other mutations that were sensitive to TKI treatment by previous reports. The 12 uncommon active mutations of EGFR were 7 for L871Q in exon 21, 1 for L858M, 1 for S768I in exon 20, 1 for G719X in exon 18, and 2 for 2-point mutations with E709G/L858R and G719X/L861Q.

The TKIs used for all patients, including gefitinib in 91 (47.9%) patients, erlotinib in 54 (28.4%), and afatinib in 45 (23.7%). 66.8% patients reported being never smokers. Malignant pleural effusion at initial diagnosis was observed in 48 (25.3%) patients. Among the patients, 152 (80%) had disease progression, and 110 (57.9%) died during follow-up.

### Table 1
Median progression-free survival and overall survival of patients with specific clinical features.

| Clinical features               | Numbers (n) | Median PFS (mo) | \( P \)-value (PFS) | Median OS (mo) | \( P \)-value (OS) |
|---------------------------------|-------------|-----------------|---------------------|----------------|-------------------|
| All patients                    | 190         | 12.0            | .357                | 23.6           | .156              |
| Age >70 yr                      | 96          | 11.43           | -                   | 19.4           | -                 |
| Age ≤70 yr                      | 94          | 14.77           | -                   | 28.07          | -                 |
| Gender Male                     | 87          | 10.4            | .004**              | 18.2           | .002**            |
| Gender Female                   | 103         | 15.17           | -                   | 35.37          | -                 |
| Smoking Ever                    | 63          | 9.63            | .<0.01**            | 15.63          | .<0.01**          |
| Smoking Never                   | 127         | 15.33           | -                   | 33.8           | -                 |
| Stage IIIb                      | 21          | 15.33           | .064                | 68.2           | .064              |
| Stage IV                        | 169         | 12              | -                   | 22.93          | -                 |
| Mutation Deletion 19            | 19          | 14.73           | .027*               | 30.47          | .<0.01**          |
| Mutation L858R                  | 89          | 11.27           | -                   | 20.43          | -                 |
| Mutation Others                 | 12          | 6.43            | -                   | 9.97           | -                 |
| Drugs Gefitinib                 | 91          | 11.43           | -                   | 19.2           | -                 |
| Drugs Erlotinib                 | 54          | 13.1            | -                   | 28.07          | -                 |
| Drugs Afatinib                  | 45          | 16.13           | .101                | 30.97          | .204              |
| Malignant pleural effusion Yes  | 48          | 10.4            | .057                | 16.33          | .01**             |
| Malignant pleural effusion No   | 142         | 12.33           | -                   | 28.07          | -                 |
| Brain metastasis Yes            | 45          | 13.57           | .49                 | 30.47          | .539              |
| Brain metastasis No             | 145         | 11.93           | -                   | 22.03          | -                 |
| Hematologic markers             |             |                 |                     |                 |                   |
| WBC count >7350/μL              | 95          | 11.03           | .002**              | 19.4           | .006**            |
| WBC count ≤7350/μL              | 95          | 14.73           | -                   | 35.07          | -                 |
| Hb >12.3g/dL                    | 93          | 12.63           | .328                | 25.97          | .49               |
| Hb ≤12.3g/dL                    | 97          | 11.53           | -                   | 22.03          | -                 |
| Platelet count >250K/μL         | 95          | 10.73           | .048*               | 20.17          | .006**            |
| Platelet count ≤250K/μL         | 95          | 14.43           | -                   | 27.3           | -                 |
| MPV>9.6fL                       | 93          | 11.8            | .624                | 23.6           | .976              |
| MPV≤9.6fL                       | 93          | 14.4            | -                   | 26.6           | -                 |
| Neutrophil% >68.7%              | 96          | 10.73           | .019*               | 18.2           | .<0.01**          |
| Neutrophil% ≤68.7%              | 94          | 15.33           | -                   | 40.3           | -                 |
| Lymphocyte% >20.8%              | 95          | 16.3            | .<0.01**            | 47.63          | .<0.01**          |
| Lymphocyte% ≤20.8%              | 95          | 9.9             | -                   | 18.07          | -                 |
| Neutrophil-to-lymphocyte ratio >3.2 | 96  | 9.07 | .003** | 18.07 | .<0.01** |
| Neutrophil-to-lymphocyte ratio ≤3.2 | 94  | 15.63 | - | 40.8 | - |
| Platelet-to-lymphocyte% ratio >12,200 | 95  | 10.73 | .011* | 17.83 | .<0.01** |
| Platelet-to-lymphocyte% ratio ≤12,200 | 95  | 15.17 | - | 35.27 | - |

* Only 186 patients had mean platelet volume (MPV) data; OS = overall survival, PFS = progression-free survival.

\* \( P \)-value < .05.

\** \( P \)-value < .01.
months, others did (median PFS: 14.73, 11.27, vs 6.43 months, types, exon 19 deletion had better PFS and OS than L858R or were associated with poor PFS and OS. About EGFR mutation

Gender (male vs female) 0.63 (0.44–0.85), 0.004**
Stage (IIb vs IV) 0.59 (0.40–1.03), .064
Mutation (Del 19 vs L858R vs others) 0.58 (0.40–0.79), .001**
Drugs (afatinib vs erlotinib vs gefitinib) - , 0.101
Malignant pleural effusion (yes vs no) 0.71 (0.47–1.12), .057
Brain metastasis (yes vs no) 1.14 (0.79–1.63), .49

Hematologic markers
WBC count (>7500 vs ≤7500/μL) 0.66 (0.47–0.92), 0.020**
Hb (>12.3 vs ≤12.3g/dL) 1.01 (0.74–1.40), .928
Platelet count (>250 vs ≤250K/μL) 0.73 (0.53–1.00), .048*
MPV (>9.6 vs ≤9.6μL) 0.92 (0.67–1.27), .624
Neutrophil% (>68.7% vs ≤68.7%) 0.69 (0.49–0.94), .019*
Lymphocyte% (>20.8% vs ≤20.8%) 1.70 (1.26–2.04), .001**
Lymphocyte-to-lymphocyte ratio (>3.2 vs ≤3.2) 0.62 (0.44–0.85), .003**
Platelet-to-lymphocyte ratio (>12,200 vs ≤12,200) 0.67 (0.46–0.91), .011

$ Only 186 patients had mean platelet volume (MPV) data; OS = overall survival.
PFS = progression-free survival.

P-value < .05.
**P-value < .01.

3.2. Clinical features versus lung adenocarcinoma under TKI treatment

Univariate analysis results showed that the male (median PFS: 10.4 vs 15.17 months, P = .0036; median OS: 18.2 vs 35.37 months, P = .002) and ever smoking (median PFS: 9.63 vs 15.33 months, P < .001; median OS 15.63 vs 33.8 months, P < .001) were associated with poor PFS and OS. About EGFR mutation types, exon 19 deletion had better PFS and OS than L858R or others did (median PFS: 14.73, 11.27, vs 6.43 months, P = .027; median OS: 30.47, 20.43, vs 9.97 months, P < .001). Malignant pleural effusion at the time of initial diagnosis was associated with poor OS only, not PFS. (median PFS: 10.4 vs 12.33 months, P = .057; median OS: 16.33 vs 28.07 months, P = .01).

Under multivariate analysis with a stepwise model, the results revealed that ever smoking was independent poor prognostic factors for PFS and OS (PFS: HR = 0.56, 95% CI: 0.40–0.79, P = .001; OS: HR = 0.55, 95% CI: 0.37–0.83, P = .004). EGFR exon 19 deletion was independent better prognostic factors for PFS and OS (PFS: HR = 1.35, 95% CI: 1.03–1.76, P = .029; OS: HR = 1.65, 95% CI: 1.20–2.29, P = .002). Malignant pleural effusion at the time of initial diagnosis was associated with poor OS still (OS: HR = 0.63, 95% CI: 0.42–0.95, P = .029). The detailed data are presented in Tables 1 and 3.

3.3. Hematologic markers versus lung adenocarcinoma under TKI treatments

Lower leukocyte count (lower than 7350/μL vs higher, median PFS: 14.73 vs 11.73 months, P = .002; median OS: 35.07 vs 19.4 months, P = .006) and lower platelet count (lower than 250,000/μL vs higher, median PFS: 14.43 vs 10.73 months, P = .048; median OS: 27.3 vs 20.17 months, P = .006) were significantly associated with a better prognosis in the univariate analysis. Higher lymphocyte percentage (higher than 20.8% vs lower, median PFS: 16.3 vs 9.9 months, P < .001; median OS: 47.63 vs 18.07 months, P < .001) was also significantly associated with better PFS and OS (Fig. 2). In the univariate analysis, the cutoff levels of NLR and PLR were established based on median values: 3.2 and 12,200. Lower NLR (median PFS: 15.63 vs 9.97 months, P = .003; median OS: 40.8 vs 18.07 months, P < .001) and lower PLR (median PFS: 15.17 vs 10.73 months, P = .011; median OS: 35.27 vs 17.83 months, P < .001) were associated with better PFS and OS.

In the multivariate analysis with a stepwise model, only higher lymphocyte percentage was significantly associated with better prognosis in PFS (HR = 1.50, 95% CI: 1.08–2.09, P = .016). Regarding OS, higher lymphocyte percentage (HR = 2.10, 95% CI: 1.39–3.17, P < .001) was also associated with a better prognosis, but higher platelet count (HR = 0.63, 95% CI: 0.43–0.93, P = .021) was associated with a significantly poorer prognosis, too.

4. Discussion

Lung cancer is a prominent global health burden that causes approximately 1.5 million annual deaths by previous reports.[19] The prognosis of patients with advanced-stage lung adenocarcinoma with genotype-driven mutations has improved owing to target therapy administration,[20,21] including in-frame deletions in exon 19 (Del19) or exon 21 substitution of leucine for arginine (L858R).[12,23] Patients with lung adenocarcinoma who harbor these classical mutations have high objective response rates to the first-generation reversible adenosine triphosphate-competitive EGFR TKIs, including gefitinib and erlotinib, and second-generation irreversible TKI, including afatinib. Despite the high response rates (52.7%–83%) of TKIs used in treating patients with stage IIIb or IV lung cancer with active EGFR mutations, such patients eventually succumb to this disease; To further improve the outcome, more aggressive treatment might be necessary for some patients. Therefore, methods for predicting prognosis have become increasingly critical. In this study, we demonstrated that lower lymphocyte percentage predicted poor
malignant pleural effusion at initial diagnosis is associated with poor outcomes in many solid cancers. Previous studies have shown that the patients with exon 19 deletions had better PFS and OS than did those with L858R. In our study, an increase in lymphocyte percentage along with smoking history were positively associated with poor prognosis by univariate analysis. Some studies showed lower NLR, or PLR ratio exhibited better prognosis in various solid tumor tissues. Thrombocytosis with a negative prognostic value in lung cancer has been reported before. However, no study has found that higher platelet count is associated with a poorer prognosis in only lung adenocarcinoma with EGFR mutations under TKI treatment. In our results, 190 patients with EGFR-mutated lung adenocarcinoma under TKI treatment demonstrated that patients with higher pretreatment platelet counts had shorter PFS and OS. Notably, under multivariate analysis, higher platelet count was found to affect only OS and not PFS. TKI treatment may be able to overcome the effects of platelet count; additional studies are required to elucidate this hypothesis.

Some studies showed lower NLR, or PLR ratio exhibited better prognosis in non-small-cell lung cancer patients. Inflammation may contribute to tumor initiation through genetic mutations, genomic instability, and epigenetic modifications, and stimulate angiogenesis, causes immunosuppression, and promotes the formation of microenvironments, and metastatic spread. Accordingly, the close association between increased systemic inflammatory responses, including NLR and PLR, and poor prognosis identified in our study may be associated with inflammatory in cancer cells.

The limitation of this study is the retrospective analysis of an observational database, and all enrolled patients were obtained from a single institution.

In conclusion, in our study of patients with stage IIIb or IV lung adenocarcinoma with EGFR mutations who received TKIs as the first-line treatment, a lower lymphocyte percentage, and higher platelet counts were significantly associated with shorter PFS and OS and higher platelet count predicted poor OS in patients with active EGFR mutations receiving TKIs as the first-line treatment.

Several retrospective studies have shown longer PFS after TKI treatment in patients harboring EGFR with exon 19 deletions than in those with exon 21 mutations. Won et al reported that 87 patients with exon 19 deletions had longer survival times significantly in our study, the patients with exon 19 deletions had better PFS and OS than those with L858R. Previous studies have shown that malignant pleural effusion at initial diagnosis is associated with poor prognosis in lung cancer patients. A recent study proposed that cancer stem cells in pleural effusion contribute to the metastatic cascade through the epithelial-mesenchymal transition, anoikis, and adaptation in the microenvironment. This result may explain the high therapeutic failure rates if the patients have malignant pleural effusion. Our results also showed the patients with malignant pleural effusion would have a poor prognosis. In addition to malignant pleural effusion and EGFR mutation sites, sex and smoking history are common prognostic factors in cancers. Our results show that male and a smoker were positively associated with poor prognosis by univariate analysis but not by multivariate analysis.

In our study, an increase in lymphocyte percentage along with a related increase in leukocyte count was associated with a better prognosis. Because lymphocytes are critical in promoting systemic immune responses against tumors, lymphocytopenia is associated with poor outcomes in many solid cancers. Cytotoxic T lymphocytes elicit adaptive cellular immunity against tumor cells and Ye et al found that high expression of CD8+ T lymphocytes predicts better prognosis in patients with lung adenocarcinoma. In our study, patients with a lymphocyte percentage of 20.8% had a better prognosis than did other patients. Higher lymphocyte percentage and lower lymphocyte percentage were associated with median OS periods of 40.63 and 18.07 months, respectively, and these were significantly different between univariate and multivariate analyses.

High platelet count has been reported with a poor prognosis in various cancers. The mechanism may be related to thymidine phosphorylase, which is a platelet-derived endothelial cell growth factor with potent angiogenic activity. An increase in thymidine phosphorylase levels may be associated with a poor prognosis in various solid tumor tissues. Thrombocytosis with a negative prognostic value in lung cancer has been reported before. However, no study has found that higher platelet count is associated with a poorer prognosis in only lung adenocarcinoma with EGFR mutations under TKI treatment. In our results, 190 patients with EGFR-mutated lung adenocarcinoma under TKI treatment demonstrated that patients with higher pretreatment platelet counts had shorter PFS and OS. Notably, under multivariate analysis, higher platelet count was found to affect only OS and not PFS. TKI treatment may be able to overcome the effects of platelet count; additional studies are required to elucidate this hypothesis.

Some studies showed lower NLR, or PLR ratio exhibited better prognosis in non-small-cell lung cancer patients. Inflammation may contribute to tumor initiation through genetic mutations, genomic instability, and epigenetic modifications, and stimulate angiogenesis, causes immunosuppression, and promotes the formation of microenvironments, and metastatic spread. Accordingly, the close association between increased systemic inflammatory responses, including NLR and PLR, and poor prognosis identified in our study may be associated with inflammatory in cancer cells.

The limitation of this study is the retrospective analysis of an observational database, and all enrolled patients were obtained from a single institution.

In conclusion, in our study of patients with stage IIIb or IV lung adenocarcinoma with EGFR mutations who received TKIs as the first-line treatment, a lower lymphocyte percentage, and higher platelet counts were significantly associated with shorter PFS and OS.
OS. Stepwise multivariate Cox regression analysis also showed that lower lymphocyte percentage was an independent poor prognostic factor for both PFS and OS, but a higher platelet count was only for OS. Further research is necessary to confirm the possible mechanism of poor prognoses.

**Author contributions**

Conceptualization: Chi-Cheng Li, Yi-Feng Wu.
Data curation: Chih-Bin Lin, Sung-Chao Chu, Jen-Jyh Lee, Gee-Gwo Yang, Tso-Fu Wang.
Methodology: Wei-Han Huang.

Formal analysis: Tso-Fu Wang, Yi-Feng Wu.
Supervision: Yi-Feng Wu.
Writing – original draft: Chi-Cheng Li, Yi-Feng Wu.

**References**

[1] Fitzmaurice C, Akinemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018;4:1553–68.

[2] Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirrology 2015;20:370–8.

Figure 2. Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS). Kaplan–Meier curves of PFS and (A) and OS (B) constructed based on the lymphocyte percentage (PFS, 9.9 vs 16.3 months, \( P = .001 \); OS, 18.07 vs 47.63 months, \( P < .001 \)). Kaplan–Meier curves of PFS (C) and OS (D) constructed based on the platelet count (PFS, 14.43 vs 10.73 months, \( P = .048 \); OS, 27.3 vs 20.17 months, \( P = .006 \)).
[3] Zamay TN, Zamay GS, Kolovskaya OS, et al. Current and prospective protein biomarkers of lung cancer. Cancers 2017.

[4] Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996;9:1826–30.

[5] Stone RL, Nick AM, McNish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610–8.

[6] Taucher S, Salat A, Gnant M, et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003;89:1098–106.

[7] Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015;33:983–91.

[8] Wu YF, Chu SC, Chang BS, et al. Hematologic markers as prognostic factors in nonmetastatic esophageal cancer patients under concurrent chemoradiotherapy. Biomed Res Int 2019;1263050.

[9] Ye SL, Li XY, Zhao K, et al. High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: a cohort study. Medicine 2017;96:e6472.

[10] Ishizuka M, Nagata H, Takagi K, et al. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol 2012;106:887–91.

[11] Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006;175:859–63.

[12] Sylman JL, Mitrugno A, Tormoen GW, et al. Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. Converg Sci Phys Oncol 2017;3.

[13] Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 2011;47:2633–41.

[14] Solinas G, Marchesi F, Garlanda C, et al. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010;29:243–52.

[15] Shibutani M, Maeda K, Nagahara H, et al. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 2013;33:3291–4.

[16] Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416–21.

[17] Unal D, Eroglu C, Kurtul N, et al. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev 2013;14:5237–42.

[18] Wang TF, Chu SC, Lee JJ, et al. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-

mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. Asia Pac J Clin Oncol 2017;13:304–13.

[19] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.

[20] Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.

[21] Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcino-
ma with EGFR mutations. J Clin Oncol 2013;31:3327–34.

[22] Paer JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.

[23] Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcino-
ma with EGFR mutations. J Clin Oncol 2013;31:3327–34.

[24] Won YW, Han JY, Lee GK, et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol 2011;64:947–52.

[25] Shriver LF, Jia S, Liu J, et al. Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. Oncol Lett 2018;16:362–70.

[26] Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl 2):ii32–40.

[27] Zhou X, Cai L, Liu J, et al. The prognostic impact of neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients with non-small cell lung cancer harbouring epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169–81.

[28] Phan TT, Ho TT, Nguyen HT, et al. The prognostic impact of neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. Int J Gen Med 2018;11:423–30.